You are here

  • Home
  • Archive
  • Volume 10, Issue Suppl 2
  • 707 A Phase 1, open-label, dose finding study of NI-1801, a bispecific mesothelin x CD47 engaging antibody, in patients with mesothelin expressing solid cancers

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trials In Progress
707 A Phase 1, open-label, dose finding study of NI-1801, a bispecific mesothelin x CD47 engaging antibody, in patients with mesothelin expressing solid cancers
Free

 

Online download statistics by month:

Online download statistics by month: November 2022 to August 2024

AbstractFullPdf
Nov 2022464033
Dec 2022102014
Jan 20234605
Feb 20238407
Mar 202350017
Apr 20238605
May 20239608
Jun 20236203
Jul 20236207
Aug 20236607
Sep 20234603
Oct 20237008
Nov 202372012
Dec 20238208
Jan 20243406
Feb 20245205
Mar 202468011
Apr 20247809
May 20246808
Jun 20243205
Jul 202494012
Aug 202492019
Total19060212